---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-001386"
form_type: "8-K"
ticker: "ADCT"
cik: "0001771910"
company_name: "ADC Therapeutics SA"
filed_at: "2026-01-08T23:59:59+00:00"
generated_at: "2026-05-16T11:14:16.064129+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# ADC Therapeutics reports preliminary 2025 revenue of ~$73M; cash runway extended to 2028

## Summary
- Preliminary Q4 2025 ZYNLONTA net product revenue ~$22M; full year 2025 ~$73M vs $69.3M in 2024.
- Cash and cash equivalents ~$261M as of Dec 31, 2025; expected cash runway at least to 2028.
- LOTIS-7 Phase 1b shows 89.8% ORR and 77.6% CR; enrollment completion expected H1 2026.
- LOTIS-5 Phase 3 topline data expected in Q2 2026; potential sBLA and approval mid-2027 if positive.
- IND-enabling activities completed for PSMA-targeting ADC; partnership opportunities being explored.

## SEC filing metadata
- accession: 0001628280-26-001386
- form_type: 8-K
- ticker: ADCT
- cik: 0001771910
- company_name: ADC Therapeutics SA
- filed_at: 2026-01-08T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1771910/000162828026001386/0001628280-26-001386-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1771910/000162828026001386/adc-20260108.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-001386
- JSON: https://secwatch.observer/filing/0001628280-26-001386.json
- Plain text: https://secwatch.observer/filing/0001628280-26-001386.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.